Key Takeaways for Thermo Fisher Scientific Stock as of July 2026
- Revenue hit $11.99 billion in the second quarter, up 10% year over year, while adjusted EPS climbed 13% to $6.03 against a Street estimate of $5.71.
- Management raised full-year guidance to $47.4 billion to $48.1 billion in revenue and $24.93 to $25.33 in adjusted EPS, now implying 9% to 11% earnings growth for 2026.
- Analytical Instruments posted the sharpest swing in the quarter: operating income jumped 30% and margin expanded 420 basis points to 23%, the widest move of any segment.
Thermo Fisher stock just cleared a bar management itself didn’t expect to clear this cleanly. Track the raised guide and the model’s next move on TIKR for free →
A Pharma Recovery Finally Shows Up in Thermo Fisher’s Numbers
Thermo Fisher Scientific (TMO) closed its books on the second quarter of 2026 with a print that outran its own prior guidance across every major line. Revenue reached $11.99 billion, up 10% year over year and roughly $300 million above what management had guided to just three months earlier. Organic growth came in at 5%, two points ahead of the company’s internal assumptions, and adjusted EPS grew 13% to $6.03 against a Street estimate of $5.71, a beat of nearly 6%.
That strength traces to a specific shift management had been waiting on. Pharma and biotech, which makes up roughly 60% of revenue, moved from stabilizing to accelerating, with bioproduction and clinical research leading the charge. Academic and government spending also returned to growth for the first time in several quarters, though executives stopped short of calling it a durable trend. CFO Jim Meyer quantified exactly where the upside came from on the Q2 2026 earnings call: adjusted EPS landed “$0.30 ahead of our previous guidance, driven by the expected pull-through from our revenue beat, strong cost productivity and excellent performance from our acquisitions, including Clario.”
Segment performance backed up that broad-based read. Analytical Instruments grew revenue 7% organically while operating margin expanded 420 basis points to 23.0%, the standout move of the quarter. Laboratory Products and Biopharma Services grew 5% organically as the recently closed Clario acquisition contributed its first full quarter of ownership. Specialty Diagnostics grew margin 70 basis points to 27.7% on volume leverage.
The guidance raise followed directly from that performance. Thermo Fisher lifted its full-year revenue range to $47.4 billion to $48.1 billion and its adjusted EPS range to $24.93 to $25.33, a $0.25 increase at the midpoint even after absorbing a $0.05 headwind from the pending divestiture of its microbiology business. Free cash flow guidance held at $6.9 billion to $7.4 billion, and the company completed $1 billion of buybacks in the quarter on top of $3 billion executed in January.
A raised guide funded by real organic acceleration, not cost cuts, is the setup TIKR’s model exists to price. Compare the new guide against the mid-case forecast on TIKR for free →
TIKR’s Model Puts Thermo Fisher Stock at $818 by Late 2030
TIKR’s mid-case model values Thermo Fisher Scientific at $818 by December 2030, implying a 43% total return from the current price of $572, or 8% annualized over roughly 4.4 years.
That 8% annualized path sits well above what a passive index return typically offers over a comparable window, positioning Thermo Fisher stock as a name the model expects to compound faster than the broader market through the back half of the decade.
The case for reaching that target runs directly through what just happened in the second quarter: a pharma and biotech recovery driving organic growth back toward the high end of guidance, margin expansion in Analytical Instruments and Life Sciences Solutions, and acquisitions like Clario adding earnings power without diluting the core franchise.
Thermo Fisher stock’s raised full-year guide gives the model’s revenue and EPS growth assumptions a fresher, higher starting point than it had three months ago.
An 8% annualized path to $818 is the kind of target that gets more credible after a quarter like this one. See the full assumptions behind the target on TIKR for free →
Should You Invest in Thermo Fisher Scientific Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Thermo Fisher Scientific Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Thermo Fisher Scientific Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze TMO stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
